Winton Group’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Winton Group’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-53,433	Closed	-$1.05M	–	1604
2019 Q4	$1.05M	Buy	+53,433	New	+$854K	0.01%	1048

Other funds holding MNTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Winton Group's MNTA Position: Q1 2020 in Review

Winton Group sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2020, closing a stake of 53,433 shares — an estimated $1.05M sold.

Winton Group first reported a position in MNTA in Q4 2019 and held it in 1 quarter. The position peaked at $1.05M in Q4 2019. 199 funds tracked by Wall St. Rank hold MNTA as of Q1 2020.

Winton Group reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Winton Group sold 53,433 Momenta Pharmaceuticals, Inc. shares in Q1 2020, an estimated $1.05M.
Winton Group first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
Winton Group's Momenta Pharmaceuticals, Inc. position peaked at $1.05M in Q4 2019.
199 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2020.

Based on Winton Group's 13F filing for Q1 2020, filed 11 May 2020.